Jardine Matheson Agrees to Buy I‑MED for $2.4 Billion as Conglomerate Moves into Healthcare
Jardine Matheson agrees to buy Australia’s I‑MED for $2.4bn, acquiring the radiology network from Permira as the group pivots into healthcare under new CEO.
Jardine Matheson has agreed to acquire 100% of Australia’s I‑MED Radiology Network for an enterprise value of $2.4 billion, marking a major purchase as the London‑listed, Asia‑focused conglomerate expands into healthcare. The deal, to buy the radiology operator from private equity firm Permira, comes amid a wider restructuring of Jardine’s businesses under its recently appointed chief executive. The acquisition positions Jardine Matheson to add diagnostic imaging capabilities to its portfolio as it seeks new growth avenues beyond traditional holdings.
Deal structure and headline terms
Jardine Matheson will pay an enterprise value of $2.4 billion for I‑MED, according to a statement from the conglomerate. The transaction covers full ownership of the Australia‑based radiology network and completes Permira’s exit as the vendor.
Details on the financing mix and the expected timetable for completion were not disclosed immediately. The companies said customary regulatory approvals and conditions precedent would apply before the transaction is finalized.
Strategic rationale under new leadership
Executives at Jardine have framed the purchase as part of a strategic shift implemented by the new CEO, who has prioritized reshaping the group’s portfolio. Moving into healthcare gives Jardine exposure to a defensive, service‑oriented sector that can complement its existing Asia‑focused investments.
Analysts note that conglomerates often seek healthcare assets to diversify revenue streams and capture predictable cash flows, particularly in markets with aging populations and rising demand for diagnostic services. The I‑MED acquisition signals Jardine’s intent to build a presence in health services beyond its historical trading and property interests.
What I‑MED does and its market footprint
I‑MED operates a network of diagnostic imaging centres across Australia, providing services such as X‑rays, CT, MRI and other radiology procedures to hospitals, clinics and outpatients. Its clinics are located in major metropolitan areas and regional centres, supplying imaging services to both public and private healthcare providers.
Industry observers say I‑MED’s platform offers immediate scale and a local operating base for Jardine to pursue further health‑care investments or partnerships in the region. The business model centres on high‑frequency diagnostic work, referral relationships with clinicians, and capital investment in imaging technology.
Seller background and private equity exit
Permira, the private equity firm selling I‑MED, is exiting a portfolio company that it had developed through buyouts and consolidation in the radiology sector. The sale to Jardine Matheson represents a common route for private equity managers to realize gains by selling to strategic buyers that can pursue long‑term operational integration.
Permira’s decision to sell follows an era of active dealmaking by private equity in healthcare, where predictable demand and margins have attracted institutional capital. The transaction provides Permira with liquidity while giving Jardine a ready‑built diagnostic network.
Regulatory and integration considerations
The transaction will be subject to regulatory review in Australia, where competition and healthcare regulators assess deals affecting service provision and patient access. Jardine and I‑MED will need to demonstrate how the acquisition will affect pricing, service continuity and investment in clinics and equipment.
Post‑deal integration will test Jardine’s ability to manage a specialized healthcare operator alongside its broader conglomerate holdings. Key priorities for the buyer will include retaining clinical staff, maintaining referral relationships, and investing to upgrade imaging capacity where needed.
Jardine Matheson’s move into healthcare will likely attract scrutiny from investors who are watching how the conglomerate balances new sector bets with its traditional businesses. The group has in recent months signalled a willingness to pivot parts of its portfolio under the CEO’s stewardship.
The deal also raises questions about future expansion: whether Jardine will pursue additional healthcare assets in Australia or other Asian markets, and how it will structure I‑MED within its existing corporate framework. Observers expect the company to outline integration plans and strategic goals once regulatory hurdles are cleared.
This acquisition underscores a larger trend in regional dealmaking, where conglomerates and strategic buyers buy specialized healthcare platforms from private equity, aiming to combine capital resources with operational scale to meet rising demand for diagnostic services.
